Our investors play a major and vital role in the success and growth of our company.
We understand and work to achieve their goals.


Prous Institute for Biomedical Research

Prous Institute for Biomedical Research was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Integrity drug discovery and development portal) acquired by Thomson Reuters in 2007. Based on its longstanding expertise in the creation and management of biomedical knowledge, the company has drug discovery programs in the fields of CNS and cancer, which have led to various preclinical candidates.


Inveready is one of the leading early-stage venture capital companies in Spain, with five investment funds. Inveready invests in technology companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 40 portfolio companies that are leaders in their respective sectors.



The Centre for the Development of Industrial Technology (CDTI) is the General State Administration body supporting knowledge-based innovation, providing guidance and public financial aid for innovation through subsidies and partially refundable grants. The CDTI also helps internationalize business R&D and innovation projects for Spanish organizations and companies, and manages Spanish participation in international R&D bodies, such as Horizon 2020 and Eureka, and in the Science and Space industries. It also supports and facilitates capitalization of technology companies through the Innvierte Economía Sostenible initiative.


Retos-Colaboración 2019

El Ministerio de Ciencia, Innovación y Universidades, dentro de la convocatoria de Proyectos de I+D+i «Retos-Colaboración» del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020, concedió ayuda al proyecto “DESARROLLO DE UNA TERAPIA PARA EL SINDROME X FRÁGIL” liderado por CONNECTA THERAPEUTICS S.L. con número de expediente RTC2019-007230-1. Este proyecto ha sido financiado por el Ministerio de Ciencia, Innovación y Universidades dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2019. El proyecto está cofinanciado por la Unión Europea con el objetivo de promover el desarrollo tecnológico, la innovación y una investigación de calidad.

The Spanish Ministry of Science, Innovation and Universities, under the call for R + D + i projects “Challenges-Collaboration” of the State Program for Research, Development and Innovation Oriented to Challenges of Society, within the framework of the State Plan for Scientific and Technical Research and Innovation 2017-2020, has granted support to the project “DEVELOPMENT OF A THERAPY FOR FRAGILE X SYNDROME” led by CONNECTA THERAPEUTICS SL, file number RTC2019-007230-1. The project is funded by the Spanish Ministry of Science, Innovation and Universities within the RETOS-COLABORACIÓN Subprogram, 2019 Call. The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.